<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03219216</url>
  </required_header>
  <id_info>
    <org_study_id>M16-156</org_study_id>
    <nct_id>NCT03219216</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naïve Adults in Brazil With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection</brief_title>
  <official_title>A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naïve Adults in Brazil With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3b, open-label, multicenter study to evaluate the efficacy and safety of
      Glecaprevir (GLE)/Pibrentasvir (PIB) combination for an 8 or 12-week treatment duration in
      adults in Brazil with chronic hepatitis C virus (HCV) genotype (GT) 1 - 6 infection, without
      cirrhosis or with compensated cirrhosis, who are HCV treatment naïve.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 30, 2018</start_date>
  <completion_date type="Anticipated">January 14, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 14, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)</measure>
    <time_frame>12 weeks after the last actual dose of study drug</time_frame>
    <description>SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification [&lt;LLOQ]) 12 weeks after the last dose of study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Post-treatment Relapse</measure>
    <time_frame>From the end of treatment through 12 weeks after the last dose of study drug</time_frame>
    <description>Post-treatment relapse was defined as confirmed HCV RNA ≥ LLOQ between the end of treatment and 12 weeks after the last dose of study drug among participants with HCV RNA levels &lt; LLOQ at the end of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With On-treatment Virologic Failure</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>On-treatment virologic failure was defined as confirmed increase of &gt; 1 log(subscript)10(subscript) IU/mL above the lowest value post-baseline HCV RNA during treatment; confirmed HCV RNA ≥ 100 IU/mL after HCV RNA &lt; LLOQ during treatment, or HCV RNA ≥ LLOQ at end of treatment with at least 6 weeks of treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hepatitis C Virus (HCV)</condition>
  <arm_group>
    <arm_group_label>Arm B Compensated Cirrhosis (F4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm B: HCV GT 1 - 6 participants with compensated cirrhosis (F4) administered GLE/PIB 300 mg/120 mg once daily (QD) for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A without Cirrhosis (F2 - F3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A: Hepatitis C virus (HCV) genotype (GT) 1 - 6 participants without cirrhosis (F2 - F3) administer Glecaprevir (GLE)/Pibrentasvir (PIB) 300 mg/120 mg once daily (QD) for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glecaprevir/Pibrentasvir</intervention_name>
    <description>Film-coated tablet</description>
    <arm_group_label>Arm A without Cirrhosis (F2 - F3)</arm_group_label>
    <arm_group_label>Arm B Compensated Cirrhosis (F4)</arm_group_label>
    <other_name>ABT-493</other_name>
    <other_name>ABT-530</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant has positive plasma hepatitis C virus (HCV) antibody and HCV ribonucleic
             acid (RNA) viral load greater than or equal to 1000 IU/mL at Screening Visit.

          -  Participant must be documented as without cirrhosis with METAVIR equivalent fibrosis
             stage of F2 - F3 or with compensated cirrhosis (F4) based on results of a liver
             biopsy, or FibroScan, or FibroTest score.

          -  Participants who are known to be HCV/Human Immunodeficiency Virus (HIV) co-infected
             may enroll if they have a positive test result for anti-HIV antibody at Screening and
             are: naïve to treatment with any antiretroviral therapy (ART), or on a stable,
             qualifying HIV ART regimen for at least 8 weeks prior to Baseline.

          -  Participants with compensated cirrhosis only: Absence of hepatocellular carcinoma
             (HCC) within 3 months prior to Screening or a negative ultrasound at Screening.

        Exclusion Criteria:

          -  Current HBV infection on screening tests.

          -  Any current or past clinical evidence of Child-Pugh B or C classification (score of &gt;
             6) or clinical history of liver decompensation including ascites on physical exam,
             including hepatic encephalopathy or variceal bleeding.

          -  Receipt of any investigational or commercially available anti-HCV agents.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>847.283.8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hosp Clinica Universidade Fede</name>
      <address>
        <city>Vitoria</city>
        <state>Espirito Santo</state>
        <zip>29 043-260</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Regiona</name>
      <address>
        <city>Maringa</city>
        <state>Parana</state>
        <zip>87083-240</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Faculdade de Med, Botucatu, BR</name>
      <address>
        <city>Botucatu</city>
        <state>Sao Paulo</state>
        <zip>18618-970</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto de Infectologia Camp</name>
      <address>
        <city>Campinas</city>
        <state>Sao Paulo</state>
        <zip>13015-080</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas da Faculdade de Medicina de Ribeirão Preto - USP</name>
      <address>
        <city>Ribeirão Preto</city>
        <state>Sao Paulo</state>
        <zip>14048-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Ernesto Dornelles</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90160-092</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Gaffree e Guinle</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20270-004</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisa Clínica do</name>
      <address>
        <city>Sao Luis</city>
        <zip>65020-600</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inst Infect Emilio Ribas</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01246-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Univ Fed Sao Paulo (UNIFESP)</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04024-002</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro e Treinamento DST/AIDS</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04121-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp Heliopolis</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04231-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas de Sao</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05403-00</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2017</study_first_submitted>
  <study_first_submitted_qc>July 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2017</study_first_posted>
  <last_update_submitted>March 9, 2018</last_update_submitted>
  <last_update_submitted_qc>March 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Hepatitis C Virus (HCV)</keyword>
  <keyword>Genotype 1 - 6</keyword>
  <keyword>Metavir System Fibrosis Score</keyword>
  <keyword>Glecaprevir</keyword>
  <keyword>Pibrentasvir</keyword>
  <keyword>Treatment naïve</keyword>
  <keyword>Cirrhosis</keyword>
  <keyword>Compensated cirrhosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

